יחס חוב לטווח קצר להון עצמי: Grace Therapeutics (GRCE)

Grace Therapeutics, Inc. (GRCE) specializes in therapies for rare nervous system pathologies, utilizing proprietary molecules to expand into global markets. The asset value tracked on this chart currently stands at 0.00. The company attracts top biochemists through a transparent corporate culture and generous stock options. Its R&D strategy is based on adapting known compounds to accelerate FDA approval, creating an efficient pipeline of innovative drugs.

Developing unique formulas to cross the blood-brain barrier requires significant capital expenditure, making liquidity control for Grace Therapeutics, Inc. (GRCE) critically important. This metric measures the ratio of short-term liabilities to equity, where reducing the share of short-term loans in equity minimizes bankruptcy risk, while the moderate use of leverage optimizes the company's overall return on assets.